Factors Associated with Low-Dose Tamoxifen Use Among Women with Atypical Hyperplasia, Lobular or Ductal Carcinoma In Situ
{{output}}
In 2019, professional guidelines incorporated low-dose tamoxifen as an option for breast cancer chemoprevention among women with atypical hyperplasia (AH), lobular or ductal carcinoma in situ (LCIS/DCIS). We assessed factors associated with low-dose tamoxifen ... ...
